Background-Prophylactic defibrillator implantation is recommended in dilated, nonischemic heart disease and left ventricular ejection fraction of ≤0.30 to 0.35. Noninvasive testing should improve accuracy in decision making of prophylactic defibrillator implantation. Methods and Results-We enrolled 60 patients (median age, 57 years) with dilated cardiomyopathy and left ventricular ejection fraction ≤0.50, and 30 control subjects (median age, 59 years) with left ventricular ejection fraction >0.50. The protocol included an initial assessment, a second assessment after 3 years, and a final follow-up: pharmacological baroreflex testing (baroreceptor reflex sensitivity), short-term spectral analysis of heart rate variability (low frequency/high frequency), and long-term time domain analysis (SD of all normal-to-normal R-R intervals), exercise microvolt T wave alternans, and signal-averaged ECG, and corrected QT-time. The median follow-up was 7 years. End points were cardiac death, resuscitated cardiac arrest, and arrhythmic death. Cardiac death was observed in 21 patients. Resuscitated cardiac arrest and arrhythmic death caused by ventricular tachyarrhythmias ≥240 per minute was observed in 7 and 10 patients, respectively. In the single time point analysis, microvolt T wave alternans, baroreceptor reflex sensitivity, and SD of all normal-to-normal R-R intervals at initial testing added significant information regarding cardiac death. Microvolt T wave alternans added information on resuscitated cardiac arrest or arrhythmic death at multiple time points (P<0.001). False-negative microvolt T wave alternans results were seen in 8% of patients. Conclusions-Noninvasive testing and left ventricular ejection fraction could not reliably identify patients with dilated cardiomyopathy at risk of fatal ventricular tachyarrhythmias. Therefore, the strategy to confine prophylactic implantable cardioverter-defibrillator implantation to patients with dilated cardiomyopathy and severely reduced LV function should be reconsidered. (Circ Arrhythm Electrophysiol. 2014;7:1101-1108.)
N onischemic, dilated cardiomyopathy (DCM) is a common cause of congestive heart failure and is a risk factor for sudden cardiac death (CD) and especially arrhythmic death (AD). 1 Current guidelines for the primary prevention with implantable cardioverter-defibrillators (ICDs) in patients with DCM are based on a few landmark trials. [2] [3] [4] Risk stratification is based on virtual borders of left ventricular ejection fraction (≤0.30-0.35) and nonsustained ventricular tachycardia (nsVT) as arrhythmia risk predictors. 5 Holter monitoring has demonstrated a prevalence of episodes of nsVT of 49% to 60%. In contrast, the annual incidence of sustained VT is remarkably low, namely 3% to 4%. 6,7 The high proportion of the remaining patients without cardiac events 8 raises the question how to discriminate high-and low-risk patients. In patients with ischemic and nonischemic cardiomyopathy, noninvasive assessments of autonomic tone and cardiac electric substrate have been developed to identify high-risk patients. [9] [10] [11] [12] [13] Combining different assessments of autonomic tone 10, 13 or combining different assessments of electric substrate 14 have given conflicting results in DCM. The objective of this article is to evaluate the clinical relevance of a combined assessment of autonomic tone plus cardiac electric substrate at multiple time points for the prediction of fatal arrhythmias in patients with DCM.
testing, and follow-up (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) were conducted at the Medical University of Vienna, Austria. Test scoring, interpretation, and statistical data processing (2009-2013) underwent a blinded assessment at the Vanderbilt Autonomic Dysfunction Center, Nashville, TN. After enrollment, optimal medical treatment was established. Test results were not disclosed to participants or their physicians. Antiarrhythmic drug therapy and ICD implantation were not guided by the study.
Population
A total of 60 patients with nonischemic, DCM and 30 control subjects without DCM were studied. Patients were eligible to participate if they were aged ≥18 years, had a left ventricular ejection fraction (LVEF) of ≤0.50 (DCM) or ≥0.50 (control subjects), had recently undergone coronary angiography with ventriculography as standard use of care independently from study participation, echocardiography, MRI at the physician's discretion, had no history of sustained ventricular arrhythmia or permanent atrial fibrillation and were nondependent on ventricular pacing.
Cardiac Electric Substrates
Corrected QT-times with Bazett formula (QTC) were obtained using automated analysis systems. nsVT and signal-averaged ECG (SAECG) were obtained using 24-hour Holter monitoring devices. nsVT was defined as a run of ≥3 ventricular beats lasting no >30 s without syncope. SAECG were obtained by time domain analysis. Late potentials were present if 2 of the following parameters were fulfilled: QRSf>114 ms, LAS40>38 ms, and RMS40<20 AV. 15 Microvolt T wave alternans (MTWA) was assessed during submaximal bicycle exercise (CH 2000; Cambridge Heart Inc, Bedford, MA). Patients were taking their regular cardiovascular medications, including β-blockers. The latter were withheld on the day of the investigation. The MTWA test was automatically interpreted (version D10) and verified. 16 
Autonomic Function
For baroreflex testing, continuous finger blood pressure by the vascular unloading technique, beat-to-beat stroke volume by impedance cardiography, and 4-lead ECG was recorded with the Task Force Monitor_system (TFM; CNSystems, Graz, Austria). 17 After a resting period in supine position of ≥30 minutes, 3 bolus injections of phenylephrine (2-4 μg/kg) were given intravenously at intervals of 10 minutes to raise systolic blood pressure by 15 to 40 mm Hg. 18 A regression line was fit between data pairs of blood pressure and R-R intervals. Only regression lines with a R 2 coefficient either ≥0.80 or statistical significant linear regression (F test on the regression model, P<0.05) were accepted. Baroreceptor reflex sensitivity (BRS, ms/ mm Hg) was obtained by calculating the mean from ≥3 slope determinations. Short-time spectral measurement of heart rate variability (HRV) was obtained during a 10-minute resting period in supine position before pharmacological baroreflex testing. 19 Time domain measures and long-term spectral parameters of HRV were obtained from 24-hour Holter recordings. The SD of all normal-to-normal R-R intervals (SDNN) was used to calculate time domain parameter for HRV.
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End Points, Classification of Death
The primary end point was time to AD or resuscitated cardiac arrest (RCA). CD and all-cause mortality were secondary end points. Deaths were categorized using an adapted form of the Hinkle classification. 20 Appropriate ICD therapy without VT acceleration that failed to save the patient's life at the time of arrhythmias was classified as AD. 21 An RCA was ventricular fibrillation or VT>240 beats per minute leading to syncope before ICD therapy, and multiple slower VT episodes (electrical storm) leading to syncope and ICD discharge without ICD therapy-related acceleration. All other ICD therapies because of VT<240 beats per minute were not taken as surrogate for AD.
Sample Size Justification and Statistical Analysis
The accrual interval will be 1 year with additional follow-up of 10 years. On the basis of our previous knowledge and literature (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) . Ineligibility was mainly because of permanent atrial fibrillation. Other patients refused participation or left ventricular ejection fraction (LVEF) normalized. During a median follow-up of 7 years, 23+1 deaths were observed. Of these, 21 were categorized as cardiac and 10 as arrhythmic. Thirteen patients had life-threatening ventricular arrhythmias as their first event, namely resuscitated cardiac arrest in 7 patients and arrhythmic death in 6 patients. Of 7 patients with resuscitated cardiac arrest *4 died later on from arrhythmic death, although an implantable cardioverter-defibrillator was implanted, 1 from noncardiac death and 2 are still alive. CSU indicates control subjects; and DCM, dilated cardiomyopathy.
review, we found that the median survival time for control patients was 15 years. If the true ratio (hazard ratio) of mortality for control subjects relative to patients with DCM is 2.5, we will need to study 56 patients with DCM and 28 control patients to be able to reject the null hypothesis that the DCM and control survival curves are equal with 80% power. The type I error probability (2 sided) associated with this test of this null hypothesis is 0.05. Data were summarized as median with 1st and 3rd quartiles or percentage (N) for continuous and categorical variables. Wilcoxon rank-sum test or Kruskal-Wallis test was used for continuous variables; χ 2 test was used for categorical variables. Survival curves were estimated by cumulative incidence treating death as the competing event and the k-sample test was used. 22 To assess whether MTWA, BRS, or SDNN adds prognostic value in addition to LVEF, we fit 4 separate Cox proportional-hazards models (all adjusted for age and sex). The added prognostic value was assessed by likelihood ratio test. All tests were 2 tailed with 5% significance level. All analyses were performed at the Vanderbilt University School of Medicine, Department of Biostatistics, Nashville, TN, using an open source software R version 3.0.2.
Results
A total of 60 patients with LVEF of ≤0.50 and 30 control patients with LVEF≥0.50 underwent serial testing. (Figure 1 , top). Distribution of LVEF and clinical characteristics of the 2 patient groups is listed in Table 1 . The median LVEF was 0.32 in patients with DCM. During a median follow-up of 7.03 years, 23 deaths in the DCM group and 1 death in the control group were observed. Of these, 21 were categorized as CD, of where 10 were considered as arrhythmic. Seven patients had a RCA (2 ventricular fibrillation and 5 fast VT). Four (Figure 1 , *) of these 7 patients died later an AD although an ICD was implanted. The remaining 3 patients together with those 10 patients who died an AD compromise 13 patients where life-threatening VTs were recorded. For further analysis, only the first event (either RCA or AD) was taken. In 7 of 10 ICD recipients (70%), ICD therapies (7 RCA events and 1 VT<220 per minute events) were recorded. In 4 patients, the ICD was unable to stop an electrical storm and the patient died an AD. Reasons for not implanting an ICD during later follow-up in a patient with LVEF ≤0.30 were patients refusal or the treatment policy of the attending physician. For mortality rates see Table 2 . Table 3 demonstrates that LVEF, first BRS, HRV testing, creatinine, and a history of syncope, and both MTWA tests were associated with the end points of AD or RCA and other forms of death. Table 4 outlines all test results stratified according to the end points cardiac (n=21) and non-CD (n=3). Besides LVEF, first BRS and first HRV assessment and both MTWA assessments were associated with cardiac and non-CD. Figure 2 demonstrates that MTWA only was associated with AD or RCA (P<0.001). We fit a Cox proportional-hazards model for the association between EF and time to RCA and AD adjusted for age and sex. We then added MTWA, BRS, and SDNN to the EF model one at a time to assess the added prognostic value. The likelihood ratio test comparing the MTWA model, BRS model, and SDNN model to the EF-only model revealed that only MTWA (P=0.018) but not BRS (P=0.349) or SDNN (P=0.192) added predictive information (Table 5) . Sensitivity, specificity, positive predictive value, and negative predictive value on the primary end points AD or RCA for MTWA for all patients were 85%, 83%, 50%, and 96% for the first assessment (I1) and 100%, 71%, 25%, and 100% for the second assessment (I2), respectively.
Test Results Related to Primary and Secondary End Points
Discussion
Our main findings are clinically important for primary prophylactic implantation of defibrillators: (1) during a median follow-up period of 7 years, the annual rate of fatal arrhythmic 
Rationale for Combined and Multiple Assessment
Our primary end point was AD or RCA. This is in contrast to other studies using sudden death as end point that is not synonymous with a fatal ventricular tachyarrhythmia. The (Q1-Q3) ; MTWA, microvolt T wave alternans; N is the number of nonmissing values; NYHA, New York Heart Association; SAECG, signal-averaged ECG; SDNN; SD of all normal-to-normal R-R intervals; and VT, ventricular tachycardia. rational for multiple testing and a projected follow-up of 10 years was the anticipated low risk of fatal arrhythmias in patients with DCM. 6 An annual total mortality rate of 5.5% compares favorably with data from previous studies. 8, 23 We found that 44% of all deaths were arrhythmic. This is in agreement with Bardy et al 24 who demonstrated that sudden CD accounts for ≤50% of all deaths in patients with DCM. In Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation, the AD rate in ICD-treated patients was 11%. 3 This discrepancy can be explained by the different length of follow-up (mean, 29 months versus median, 7 years). We are in agreement with Ellenbogen et al 25 who observed that twice as many patients experienced appropriate ICD therapies when compared with the patients dying a sudden, AD: we observed that 7 of 10 patients had ICD intervention and 4 of 10 patients died an AD. Both Cardiomyopathy Trial (CAT) 2 and Amiodarone versus Implantable Defibrillator (AMIOVIRT) 8 have failed to demonstrate a survival benefit in patients treated with prophylactic ICDs. High numbers of ICD implants to save one life (14 ICDs within 5 years) have been already postulated in Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 4 In our study 13 of 60 patients died an AD during follow-up.
Microvolt T Wave Alternans
The role of MTWA in predicting AD in DCM is controversial in the literature. In good accordance with our data, most studies have shown that abnormal MTWA test results indicate an increased risk of death or fatal arrhythmias.
11,12,14,26 However, in most studies, one of the reasons for the low positive predictive value of MTWA testing in AD prediction is the reported high rates of abnormal results (37%-51%) and the low event rate within a short follow-up period. In contrast, in our study, the high event rate together with the overall high rate of negative MTWA test results contributed to the positive predictive value of 50%. However, depending on the point in time of MTWA assessment, the percentage of patients missed at risk is as high as 8. In addition, in our population, 5% of patients could not be included because of permanent atrial fibrillation.
SAECG and nsVT
The role of SAECG is controversial in the literature. Some studies have indicated the usefulness of SAECG for risk stratification, 27, 28 whereas in others 29 it was not a significant predictor for arrhythmias. Documentation of nsVT in Holter recordings has been shown to predict mortality in some studies, 6 ,30 whereas others 31 found no correlation. The role of PVS is unclear, 32, 33 and positive studies are rare. 34 In the present study, neither SAECG nor the presence of nsVT on Holter recordings was found to be useful in fatal arrhythmic risk prediction.
Markers of Autonomic Tone: HRV and BRS
It is common that HRV in patients with heart failure is assessed by time domain analysis (SDNN) of Holter recordings and spectral analysis (low frequency/high frequency) of long-term Holter recordings. In our study, we performed additional pharmacological BRS testing with phenylephrine bolus administration and together with short-term spectral analysis of previous data during resting supine baseline. Several studies indicated the usefulness of these markers in risk stratification, 3, 9, 12 whereas some studies also did not identify significant findings for the prediction of arrhythmic mortality. 5, 13 In our study, only the initial HRV and BRS were found to be predictive for CD and for AD or RCA. BRS indicates baroreceptor reflex sensitivity; CI, confidence interval; MTWA, microvolt T wave alternans; LVEF, left ventricular ejection fraction; SDNN, SD of all normal-to-normal R-R intervals; and U, unit(s).
Role of LVEF
The reason to choose an upper LVEF limit of 0.50 was based on the Autonomic Tone and Reflexes After Myocardial Infarction (ATRAMI) study, 18 where a relative risk of 2.5 for cardiac mortality in patients with an LVEF between 0.35 and 0.50 when compared with patients with LVEF≥0.50 was found. Primary preventive ICD trials used LVEF as main inclusion criterion with the hypothesis that fatal arrhythmic events play a major role. Of note, these studies were not designed to evaluate LVEF as risk stratification technique. One of our findings is that reduced LVEF is associated with increased cardiac mortality but not with increased AD or RCA. The majority of patients with sudden CD have an LVEF ≥0.30 and even ≥0.40, respectively. 35 In our study, 22% of patients with an LVEF≥0.30 had fatal ventricular arrhythmias as their first event.
Limitations
This was a nonrandomized, prospective, observational study performed to assess the risk of fatal arrhythmias during longterm follow-up. It is still possible that some of the events, defined as RCA, might not have led to death. Another limitation is the small sample size, which does not allow making firm conclusions. Therefore, any finding should be labeled as pilot study results.
Conclusions
One quarter of patients with nonischemic, dilated heart disease, and LVEF≤0.50 experience fatal arrhythmias. The occurrence of fatal arrhythmias is not dependent on the degree of LVEF reduction. In DCM, none of the noninvasive risk stratification techniques seem useful in clinical decision making. Therefore, the strategy to confine prophylactic ICD implantation to patients with DCM and severely reduced LV function should be reconsidered.
